Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$10.35 +4.5%	$7.93	$5.51 ▼ $11.73	$202.16M	N/A	47,566 shs	23,090 shs
PMVP PMV Pharmaceuticals	$0.88 -0.1%	$1.07	$0.82 ▼ $2.26	$45.86M	1.5	237,728 shs	32,401 shs
TVGN Tevogen Bio	$1.09 +0.4%	$1.07	$0.26 ▼ $3.09	$201.29M	-0.82	5.11 million shs	722,092 shs
VYGR Voyager Therapeutics	$3.24 -5.5%	$3.52	$2.75 ▼ $9.55	$179.21M	0.95	445,631 shs	756,113 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+5.16%	+2.95%	+40.32%	+11.01%	+977,999,900.00%
PMVP PMV Pharmaceuticals	-0.67%	-11.62%	-1.80%	-38.63%	-59.08%
TVGN Tevogen Bio	+5.31%	+11.41%	+13.54%	-25.85%	+9.00%
VYGR Voyager Therapeutics	+4.73%	-3.24%	+20.53%	-36.62%	-59.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	1.851 of 5 stars	3.6	2.0	0.0	0.0	0.6	1.7	0.6
TVGN Tevogen Bio	2.4689 of 5 stars	3.5	2.0	0.0	0.0	0.0	2.5	0.0
VYGR Voyager Therapeutics	4.6336 of 5 stars	4.6	1.0	0.0	4.6	2.5	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	98.07% Upside
PMVP PMV Pharmaceuticals	3.25	Buy	$5.67	541.97% Upside
TVGN Tevogen Bio	3.00	Buy	$7.10	548.64% Upside
VYGR Voyager Therapeutics	3.11	Buy	$13.97	331.06% Upside

Current Analyst Ratings Breakdown

Latest PMVP, TVGN, ACTU, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/21/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/20/2025	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/17/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
3/13/2025	VYGR Voyager Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
3/13/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/12/2025	VYGR Voyager Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
3/12/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/12/2025	VYGR Voyager Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$4.41 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($1.10) per share	N/A
VYGR Voyager Therapeutics	$80.00M	2.24	$2.30 per share	1.41	$5.37 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$24.75M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	-$68.96M	-$1.14	N/A	N/A	N/A	N/A	-24.20%	-21.67%	5/9/2025 (Estimated)
TVGN Tevogen Bio	-$70K	N/A	0.00	∞	N/A	N/A	-396.07%	749.97%	N/A
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.56	N/A	N/A	15.80%	8.33%	6.15%	5/12/2025 (Estimated)

Latest PMVP, TVGN, ACTU, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	PMVP PMV Pharmaceuticals	-$0.37	-$0.34	+$0.03	-$0.34	N/A	N/A
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million
3/3/2025	Q4 2024	PMVP PMV Pharmaceuticals	-$0.37	-$0.45	-$0.08	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	1.68	1.68
PMVP PMV Pharmaceuticals	N/A	13.98	13.98
TVGN Tevogen Bio	N/A	0.34	0.34
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
PMVP PMV Pharmaceuticals	90.20%
TVGN Tevogen Bio	N/A
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
PMVP PMV Pharmaceuticals	7.60%
TVGN Tevogen Bio	56.60%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.53 million	N/A	N/A
PMVP PMV Pharmaceuticals	50	51.95 million	47.81 million	Optionable
TVGN Tevogen Bio	3	183.89 million	75.97 million	N/A
VYGR Voyager Therapeutics	100	55.31 million	52.15 million	Optionable

PMVP, TVGN, ACTU, and VYGR Headlines

Recent News About These Companies

Voyager Therapeutics, Inc.: Voyager Reports First Quarter 2025 Financial and Operating Results

May 9 at 10:49 PM | finanznachrichten.de

Analysts Set Expectations for VYGR FY2029 Earnings

May 9 at 4:15 AM | americanbankingnews.com

Raymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

May 9 at 3:27 AM | marketbeat.com

Neurocrine hands back 2 CNS gene therapy programs to Voyager

May 7 at 12:13 PM | fiercebiotech.com

Voyager Therapeutics (VYGR) Expected to Announce Quarterly Earnings on Monday

May 7 at 8:28 AM | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates

May 6 at 6:10 PM | zacks.com

Voyager Reports First Quarter 2025 Financial and Operating Results

May 6 at 4:01 PM | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Renaissance Technologies LLC

May 4, 2025 | marketbeat.com

Institutional Shifts at Voyager Therapeutics Reflect Trends in NASDAQ Companies by Market Cap

May 2, 2025 | kalkinemedia.com

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

April 28, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from Brokerages

April 22, 2025 | marketbeat.com

Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

April 21, 2025 | finance.yahoo.com

FY2026 Earnings Forecast for VYGR Issued By Leerink Partnrs

April 20, 2025 | marketbeat.com

7 Analysts Assess Voyager Therapeutics: What You Need To Know

April 10, 2025 | nasdaq.com

Voyager Therapeutics (NASDAQ:VYGR) Receives "Buy" Rating from HC Wainwright

April 10, 2025 | marketbeat.com

Voyager updates on Alzheimer’s programs ‘compelling,’ says H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

ADAR1 Capital Management LLC Acquires 86,158 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

April 9, 2025 | marketbeat.com

TD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

April 8, 2025 | markets.businessinsider.com

2VYGR : 7 Analysts Assess Voyager Therapeutics: What You Need To Know

April 8, 2025 | benzinga.com

Alfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

April 6, 2025 | insidertrades.com

Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025

April 2, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom
By Nathan Reiff | April 10, 2025
View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom
Rockwell Automation: Tailwinds From Onshoring U.S. Production
By Thomas Hughes | May 8, 2025
View Rockwell Automation: Tailwinds From Onshoring U.S. Production

PMVP, TVGN, ACTU, and VYGR Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$10.35 +0.45 (+4.55%)

As of 03:59 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

PMV Pharmaceuticals NASDAQ:PMVP

$0.88 0.00 (-0.12%)

As of 04:00 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Tevogen Bio NASDAQ:TVGN

$1.09 +0.00 (+0.42%)

As of 03:57 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Voyager Therapeutics NASDAQ:VYGR

$3.24 -0.19 (-5.54%)

As of 03:59 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time